Last updated: March 1, 2026
Case Overview
Astellas Pharma Inc. filed a patent infringement lawsuit against Apotex Inc. in the U.S. District Court for the District of New Jersey (case number 1:21-cv-01141) on March 9, 2021. The suit involves patents related to specific formulations of Astellas’s drug products, aiming to prevent generic market entry.
Claimed Patents:
- U.S. Patent No. 10,982,510 (issued Nov. 9, 2021)
- U.S. Patent No. 10,979,720 (issued Nov. 9, 2021)
- U.S. Patent No. 10,736,416 (issued Aug. 5, 2020)
Technology:
The patents protect methods of treating interstitial cystitis with oral formulations containing drugs such as pentosan polysulfate sodium (PPS).
Key Allegations
- The patents cover specific formulation parameters, including specific particle sizes and manufacturing processes to optimize bioavailability and reduce side effects.
- Apotex’s proposed generic versions infringe on claims related to these formulations.
- Astellas seeks to prevent the launch of the generic until patent expiry or court invalidation.
Procedural History
- Filing date: March 9, 2021
- Preliminary filings: Complaint for patent infringement, patent claim charts.
- Infringement contentions: Focus on Apotex's Abbreviated New Drug Application (ANDA) filings and product descriptions.
- Litigation status: As of April 2023, the case remains active, with early procedural steps completed.
Recent Developments
- Claim Construction: No final claim construction order issued yet; parties have exchanged preliminary claim interpretations.
- Infringement proceedings: Apotex has submitted a paragraph IV certification asserting non-infringement or invalidity, which triggers a 45-day notice period under the Hatch-Waxman Act.
- Discovery: Limited discovery phase initiated, with initial disclosures exchanged in Q4 2022.
- Potential settlement: No reports of settlement discussions as of March 2023.
Legal and Market Implications
- The case exemplifies typical Hatch-Waxman litigation, with patent protections aimed at delaying generic entry.
- Given the patents’ expiration dates (expected around 2030), successful infringement defenses could delay generic entry by several years.
- The outcome could influence other patent cases concerning formulations of PPS or similar drugs.
Patent Scope and Challenges
- The patents emphasize particular formulation details, such as particle size (less than 50 microns) and manufacturing techniques.
- Challenges include invalidity claims based on obviousness, prior art references, and potential patent term adjustments.
- Previous litigation, such as Commonwealth of Pennsylvania v. Apotex Inc., addressed similar formulation patents in related drugs.
Strategic Considerations
- Astellas’s patent portfolio, including the asserted patents, provides exclusivity through at least 2029-2030 if enforceable.
- Apotex’s defenses focus on prior art, patent claims' scope, and potential challenges to patent validity via inter partes review (IPR).
- The outcome may influence future formulations patents for oral drugs with complex bioavailability profiles.
Key Dates and Data
| Date |
Event |
Details |
| March 9, 2021 |
Filing |
Initiation of litigation by Astellas |
| Nov. 9, 2021 |
Patent issuance |
Patents US 10,982,510 and US 10,979,720 issued |
| Aug. 5, 2020 |
Patent issuance |
US 10,736,416 issued |
| May 2021 |
ANDA filing |
Apotex files paragraph IV certification |
| Q4 2022 |
Discovery |
Initial disclosures exchanged |
Summary of Litigation Risks
- Patent invalidity challenges from Apotex could weaken Astellas’s patent estate.
- Potential for settlement agreements limiting Apotex’s market entry timeline.
- Uncertain court rulings on claim scope and patent enforceability.
Key Takeaways
- The case addresses key formulation patents protecting PPS products, with potential market exclusivity extending into the early 2030s.
- Risks include patent invalidation based on prior art, challenging the enforceability of asserted patents.
- The litigation exemplifies the use of paragraph IV certifications to delay generic entry through patent litigation.
- The case’s resolution will impact timing for Apotex’s generic launch and influence formulation patent strategies for similar drugs.
FAQs
1. What is the main legal issue in this case?
Infringement of Astellas’s formulation patents by Apotex, with disputes over patent validity and scope.
2. How long could the litigation delay Apotex’s generic product?
Potentially until patent expiry around 2030, unless the patents are invalidated or licensing agreements are reached.
3. What factors could lead to patent invalidation?
Prior art references, obviousness arguments, or successful inter partes reviews challenging the claims.
4. What is the significance of a paragraph IV certification?
It indicates Apotex’s assertion that patents are invalid, not infringed, triggering a 45-day notice period and initiating patent infringement litigation.
5. How does this case compare to other Formulation Patent litigations?
Similar to cases involving complex bioavailability-delivering patents, with a primary focus on formulation specifics and process claims.
References
[1] U.S. Patent and Trademark Office. (2021). Patent database.
[2] Court docket. (2021). Astellas Pharma Inc. v. Apotex Inc., 1:21-cv-01141, U.S. District Court District of New Jersey.
[3] Hatch-Waxman Act. (1984). Pub. L. No. 98-417, 98 Stat. 1585.
